Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ELACOI (lopinavir/ritonavir), 2020 NCT04252885

lopinavir/ritonavir (n=21) vs. standard of care (n=7)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Lopinavir-ritonavir
Lopinavir (200mg) boosted by ritonavir (50mg) (oral, q12h, 500 mg each time for 7-14 days) monotherapy

Control treatment

Standard of care.
No antiviral medication. Supportive care and effective oxygen therapy if in need.

3 arms: lopinavir/ritonavir (n=21), arbidol=umifénovir (n=16) and standard of care (n=7).Standard of care in both groups.

Patients

COVID-19 mild to moderate

Method

Open-label

China, single center

Remark